{"slideshow_credits": null, "snippet": "Some see ketamine as an effective drug for some patients, and others see it as a dangerous hallucinogen that has not been studied enough.", "abstract": "Small studies at prestigious medical centers suggest that ketamine, anesthetic widely abused as a club drug, can relieve depression in many people who are not helped by conventional antidepressants; some psychiatrists express alarm that clinics are springing up to offer ketamine treatments for depression; pharmaceutical companies are aiming to develop drugs that work like ketamine but without side effects.", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK", "contributor": ""}, "web_url": "http://www.nytimes.com/2014/12/10/business/special-k-a-hallucinogen-raises-hopes-and-concerns-as-a-treatment-for-depression.html", "lead_paragraph": "Some see ketamine as an effective drug for some patients, and others see it as a dangerous hallucinogen that has not been studied enough.", "headline": {"main": "Special K, a Hallucinogen, Raises Hopes and Concerns as a Treatment for Depression", "print_headline": "Club Drug Gets a Second Look"}, "_id": "5487b13338f0d8602128e724", "word_count": "1415", "multimedia": [{"height": 126, "url": "images/2014/12/10/business/drug2/drug2-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2014/12/10/business/drug2/drug2-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 900, "url": "images/2014/12/10/business/drug2/drug2-articleLarge.jpg", "legacy": {"xlarge": "images/2014/12/10/business/drug2/drug2-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "900"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2014/12/10/business/drug2/drug2-thumbStandard.jpg", "legacy": {"thumbnail": "images/2014/12/10/business/drug2/drug2-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2014-12-10T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Depression (Mental)", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Antidepressants", "name": "subject", "is_major": "N", "rank": "3"}, {"value": "Therapy and Rehabilitation", "name": "subject", "is_major": "N", "rank": "4"}, {"value": "Clinical Trials", "name": "subject", "is_major": "N", "rank": "5"}, {"value": "Mental Health and Disorders", "name": "subject", "is_major": "N", "rank": "6"}], "blog": [], "subsection_name": null, "type_of_material": "News"}